ER+/HER2+ Metastatic Breast Cancer
1 Pogledi
administrator
07/03/23
Hope S. Rugo, MD, looks at the use of CDK4/6 inhibitors for patients with metastatic ER-positive, HER2-positive breast cancer and the trials evaluating their use in this setting.
Prikaži više
Komentari na Facebooku
Nema komentara